Moderna Inc (WBO:MRNA)
€ 38.03 -0.48 (-1.25%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 53/100

Moderna Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 06:10PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Moderna with us today. And with us is Stéphane Bancel, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

So Stéphane, to start here, just given the COVID-19 pandemic, Moderna has the opportunity here to demonstrate the potential of the mRNA platform as it relates to vaccine development over the course of a few months versus what would have typically taken 2 to 5 years or maybe even more. Why is Moderna positioned to successfully develop a vaccine and supply it to the global population?

StÃ;phane Bancel
Moderna, Inc. - CEO & Director

© -

Yes. So Salveen, good afternoon, and thank you for having us. I think a few reasons. I mean first, we believed since we started the company, that mRNA could be potentially the best

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot